上海医药 reported revenue of ¥147.47B for the period ended 2026-06-30, +4.2% year on year. Net income was ¥4.34B, a 2.9% net margin on a 11.0% gross margin. The largest revenue line is 分销 at 91% of the total. Free cash flow for the period was ¥5.11B.
| Item | Amount | Y/Y |
|---|---|---|
| Revenue | ¥147.47B | +4.2% |
| Gross profit | ¥16.26B | — |
| Operating income | ¥5.64B | — |
| Net income | ¥4.34B | -13.1% |
| Gross margin | 11.0% | Net margin 2.9% |
| Revenue Q/Q | -4.1% | — |
| Segment | Revenue | Share |
|---|---|---|
| 分销 | ¥134.41B | 91.1% |
| 工业 | ¥13.19B | 8.9% |
| 零售 | ¥4.09B | 2.8% |
| 其他 | ¥0.86B | 0.6% |
| 分部间抵销 | ¥-5.08B | -3.4% |
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | ¥131.21B | 89.0% |
| R&D | ¥0.97B | 0.7% |
| SG&A | ¥9.28B | 6.3% |
| Tax & other | ¥1.30B | 0.9% |
| Item | Amount |
|---|---|
| Total assets | ¥240.77B |
| Total liabilities | ¥147.98B |
| Shareholders' equity | ¥92.79B |
| Equity / assets | 38.5% |
| Operating cash flow | ¥5.46B |
| Capital expenditure | ¥0.35B |
| Free cash flow | ¥5.11B |
| Cash conversion (OCF / net income) | 102% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
中国中冶 ・ 中国人寿 ・ 长城汽车 ・ 邮储银行 ・ 中国建筑 ・ 中国电建 ・ 华泰证券 ・ 拓普集团 ・ 中国卫通 ・ 上海电气 ・ 中国电信 ・ 中国中车
Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies